Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Sees Large Volume Increase - Here's What Happened

Key Points

• Trading volume surged 270% as 413,801 shares changed hands, while the ADR last traded at $10.7350, down about 1.1% from the prior close of $10.83.
• The company posted an earnings beat for the quarter with EPS of $0.28 vs. $0.19 expected and revenue of $966.53 million versus $848.42 million forecast.
• Shionogi shows solid fundamentals with a market cap of $18.22 billion, a P/E of 14.09 and PEG of 1.09, plus very low debt-to-equity (0.01) and strong liquidity (quick ratio 5.21, current ratio 5.84) and a net margin of 41.82%.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) shares saw strong trading volume on Friday . 413,801 shares were traded during trading, an increase of 270% from the previous session's volume of 111,869 shares.The stock last traded at $10.7350 and had previously closed at $10.83.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 1.1%

The stock has a market cap of $18.22 billion, a price-to-earnings ratio of 14.09, a PEG ratio of 1.09 and a beta of 0.17. The business's 50 day moving average is $10.27 and its 200-day moving average is $9.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.21 and a current ratio of 5.84.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last posted its quarterly earnings data on Friday, January 30th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.09. The company had revenue of $966.53 million during the quarter, compared to analysts' expectations of $848.42 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.82% and a return on equity of 13.70%. On average, sell-side analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company's product portfolio spans both established and innovative therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.